Literature DB >> 31325308

Cardiovascular risk factors associated with polymyalgia rheumatica and giant cell arteritis in a prospective cohort: EPIC-Norfolk Study.

Max Yates1, Robert Luben2, Shabina Hayat2, Sarah L Mackie3, Richard A Watts1, Kay-Tee Khaw2, Nick J Wareham4, Alex J MacGregor1.   

Abstract

OBJECTIVES: PMR and GCA are associated with increased risk of vascular disease. However, it remains unclear whether this relationship is causal or reflects a common underlying propensity. The aim of this study was to identify whether known cardiovascular risk factors increase the risk of PMR and GCA.
METHODS: Clinical records were examined using key word searches to identify cases of PMR and GCA, applying current classification criteria in a population-based cohort. Associations between cardiovascular risk factors and incident PMR and GCA were analysed using Cox proportional hazards.
RESULTS: In 315 022 person years of follow-up, there were 395 incident diagnoses of PMR and 118 incident diagnoses of GCA that met the clinical definition. Raised diastolic blood pressure (>90 mmHg) at baseline/recruitment was associated with subsequent incident PMR [hazard ratio=1.35 (95% CI 1.01, 1.80) P=0.045], and ever-smoking was associated with incident GCA [hazard ratio=2.01 (95% CI 1.26, 3.20) P=0.003]. Estimates were similar when the analysis was restricted to individuals whose diagnoses satisfied the current classification criteria sets.
CONCLUSION: PMR and GCA shares common risk factors with vascular disease onset, suggesting a common underlying propensity. This may indicate a potential for disease prevention strategies through modifying cardiovascular risk.
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  cardiovascular disease; giant cell arteritis; polymyalgia rheumatica

Mesh:

Year:  2020        PMID: 31325308      PMCID: PMC7243373          DOI: 10.1093/rheumatology/kez289

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  20 in total

1.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis.

Authors:  G G Hunder; D A Bloch; B A Michel; M B Stevens; W P Arend; L H Calabrese; S M Edworthy; A S Fauci; R Y Leavitt; J T Lie
Journal:  Arthritis Rheum       Date:  1990-08

2.  Smoking as a risk factor for giant cell arteritis: A systematic review and meta-analysis.

Authors:  David N Brennan; Patompong Ungprasert; Kenneth J Warrington; Matthew J Koster
Journal:  Semin Arthritis Rheum       Date:  2018-07-11       Impact factor: 5.532

3.  [Epidemiologic approach to Horton's disease in the department of Loire-Atlantique. 110 cases in 10 years (1970-1979)].

Authors:  J Barrier; P Pion; R Massari; P Peltier; J Rojouan; J Y Grolleau
Journal:  Rev Med Interne       Date:  1982-03       Impact factor: 0.728

4.  Giant cell arteritis and vascular disease-risk factors and outcomes: a cohort study using UK Clinical Practice Research Datalink.

Authors:  Lin Li; Tuhina Neogi; Susan Jick
Journal:  Rheumatology (Oxford)       Date:  2017-05-01       Impact factor: 7.580

Review 5.  Coronary artery disease in giant cell arteritis: a systematic review and meta-analysis.

Authors:  Patompong Ungprasert; Matthew J Koster; Kenneth J Warrington
Journal:  Semin Arthritis Rheum       Date:  2014-10-29       Impact factor: 5.532

6.  Body mass index and the risk of giant cell arteritis: results from a prospective study.

Authors:  Karin Jakobsson; Lennart Jacobsson; Kenneth Warrington; Eric L Matteson; Kimberly Liang; Olle Melander; Carl Turesson
Journal:  Rheumatology (Oxford)       Date:  2014-09-05       Impact factor: 7.580

7.  Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or Cerebrovascular Disease? A Clinical Practice Research Datalink Study.

Authors:  Joanna C Robson; Amit Kiran; Joe Maskell; Andrew Hutchings; Nigel Arden; Bhaskar Dasgupta; William Hamilton; Akan Emin; David Culliford; Raashid Luqmani
Journal:  J Rheumatol       Date:  2016-04-15       Impact factor: 4.666

8.  2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.

Authors:  Bhaskar Dasgupta; Marco A Cimmino; Hilal Maradit-Kremers; Wolfgang A Schmidt; Michael Schirmer; Carlo Salvarani; Artur Bachta; Christian Dejaco; Christina Duftner; Hanne Slott Jensen; Pierre Duhaut; Gyula Poór; Novák Pál Kaposi; Peter Mandl; Peter V Balint; Zsuzsa Schmidt; Annamaria Iagnocco; Carlotta Nannini; Fabrizio Cantini; Pierluigi Macchioni; Nicolò Pipitone; Montserrat Del Amo; Georgina Espígol-Frigolé; Maria C Cid; Víctor M Martínez-Taboada; Elisabeth Nordborg; Haner Direskeneli; Sibel Zehra Aydin; Khalid Ahmed; Brian Hazleman; Barbara Silverman; Colin Pease; Richard J Wakefield; Raashid Luqmani; Andy Abril; Clement J Michet; Ralph Marcus; Neil J Gonter; Mehrdad Maz; Rickey E Carter; Cynthia S Crowson; Eric L Matteson
Journal:  Ann Rheum Dis       Date:  2012-04       Impact factor: 19.103

9.  Associations between polymyalgia rheumatica and giant cell arteritis and 12 cardiovascular diseases.

Authors:  Mar Pujades-Rodriguez; Bram Duyx; Sara L Thomas; Dimitris Stogiannis; Liam Smeeth; Harry Hemingway
Journal:  Heart       Date:  2016-01-19       Impact factor: 5.994

10.  Usual blood pressure, peripheral arterial disease, and vascular risk: cohort study of 4.2 million adults.

Authors:  Connor A Emdin; Simon G Anderson; Thomas Callender; Nathalie Conrad; Gholamreza Salimi-Khorshidi; Hamid Mohseni; Mark Woodward; Kazem Rahimi
Journal:  BMJ       Date:  2015-09-29
View more
  1 in total

Review 1.  One Giant Step for Giant Cell Arteritis: Updates in Diagnosis and Treatment.

Authors:  Marc Dinkin; Editha Johnson
Journal:  Curr Treat Options Neurol       Date:  2021-01-16       Impact factor: 3.598

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.